FOR IMMEDIATE RELEASE 30 NOVEMBER 2015
TR-1 NOTIFICATION OF MAJOR INTEREST IN SHARES BY AVIVA
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, confirms that it has received a TR-1 by Aviva plc, providing an update on its direct and indirect share allocation via its subsidiaries. The total holding remains the same at 8,140,848 Ordinary Shares or 9.19% of the issued share capital. Aviva is one of the largest institutional shareholders in ImmuPharma.
The full TR-1 disclosure can be seen below.
For further information please contact:
ImmuPharma plc |
+ 44 (0) 20 7152 4080 |
Tim McCarthy, Chairman |
|
Lisa Baderoon, Head of Investor Relations |
+ 44 (0) 7721 413496 |
|
|
Panmure, Gordon & Co., NOMAD & Broker |
+44 (0) 20 7886 2500 |
Fred Walsh, Duncan Monteith, Corporate Finance Charles Leigh-Pemberton, Corporate Broking
|
|
TR-1 : MAJOR INTEREST IN SHARES
1. Identity of the issuer or the underlying issuer |
Immupharma plc |
|||
2 Reason for the notification (please tick the appropriate box or boxes): |
||||
An acquisition or disposal of voting rights |
|
|||
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached |
|
|||
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments |
|
|||
An event changing the breakdown of voting rights |
|
|||
Other (please specify): |
NOTIFICATION PROMPTED BY THE REMOVAL OF STOCK LENDING EXEMPTION FOLLOWING IMPLEMENTATION OF THE EU TRANSPARENCY DIRECTIVE AMENDMENTS |
x |
||
3. Full name of person(s) subject to the |
Aviva plc & its subsidiaries |
|||
4. Full name of shareholder(s) |
Registered Holder:
BNY Norwich Union Nominees Limited 232,080*
Chase (GA Group) Nominees Limited 6,809,654*
*denotes direct interest
Chase (GA Group) Nominees Limited 373,991
Chase Nominees Limited 150,841
Vidacos Nominees Limited 406,282
|
|||
5. Date of the transaction and date on |
25 November 2015 |
|||
6. Date on which issuer notified: |
27 November 2015 |
|||
7. Threshold(s) that is/are crossed or |
8% to 7% Change at Direct Interest Level |
|||
8. Notified details: |
||||||||||
A: Voting rights attached to shares viii, ix |
||||||||||
Class/type of
|
Situation previous |
Resulting situation after the triggering transaction |
||||||||
Number |
Number |
Number |
Number of voting |
% of voting rights x |
||||||
Direct |
Direct xi |
Indirect xii |
Direct |
Indirect |
||||||
Ordinary Shares
GB0033711010 |
8,143,876 |
8,143,876 |
7,972,848 |
7,041,734 |
931,114 |
7.95% |
1.05% |
|||
|
||||||||||
|
||||||||||
B: Qualifying Financial Instruments |
||||||||||
Resulting situation after the triggering transaction |
||||||||||
Type of financial |
Expiration |
Exercise/ |
Number of voting |
% of voting |
||||||
|
|
|
|
|
||||||
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi |
||||||
Resulting situation after the triggering transaction |
||||||
Type of financial |
Exercise price |
Expiration date xvii |
Exercise/ |
Number of voting rights instrument refers to
|
% of voting rights xix, xx
|
|
RIGHT TO RECALL LOANED SHARES |
N/A |
N/A |
N/A |
168,000 *
* Direct interest |
Nominal |
Delta |
0.19% |
|
Total (A+B+C) |
|
Number of voting rights |
Percentage of voting rights |
8,140,848 |
9.19% |
9. Chain of controlled undertakings through which the voting rights and/or the |
||
The voting rights are managed and controlled by Aviva Investors Global Services Limited, with the following chain of controlled undertakings:-
Aviva Investors Global Services Limited: · Aviva plc (Parent Company) · Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc) · Aviva Investors Holdings Limited (wholly owned subsidiary of Aviva Group Holdings Limited) · Aviva Investors Global Services Limited (wholly owned subsidiary of Aviva Investors Holdings Limited)
|
||
|
||
Proxy Voting: |
||
10. Name of the proxy holder: |
See Section 4 |
|
11. Number of voting rights proxy holder will cease |
|
|
12. Date on which proxy holder will cease to hold |
|
|
|
||
|
|
|
14. Contact name: |
Neil Whittaker, Aviva plc |
|
15. Contact telephone number: |
01603 684420 |
|